Drug Trial Radar · NCT07477587
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
258
Planned (sponsor's estimate)
Start
May 25, 2026
Primary completion
May 25, 2027
Study completion Feb 22, 2028
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Mar 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the pharmacokinetic (PK) similarity, safety, tolerability, immunogenicity, and efficacy of HLX15-SC versus US-DARZALEX FASPRO® following single and multiple subcutaneous (SC) injections in newly diagnosed MM patients ineligible for transplant. Participants who meet all inclusion criteria and none of the exclusion criteria will receive either the HLX15-SC-Rd regimen or the D-Rd regimen for 4 cycles (one cycle = 4 weeks). After 4 cycles of treatment, based on clinical benefit and participant preference, participants may continue to receive the locally marketed daratumumab subcutaneous formulation (Dara-SC) in combination with Rd according to clinical practice, up to 32 weeks or until loss of clinical benefit, death, unacceptable toxicity, withdrawal of informed consent, or any other protocol-specified reason, whichever occurs first. After 32 weeks of dosing, participants will continue to receive appropriate standard of care according to local guidelines (including marketed Dara-SC).
Conditions
- Multiple Myeloma (MM)
Interventions
HLX15-SC-RdDrug
Subjects will receive 1800 mg HLX15-SC via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).
US-DARZALEX FASPRO®-RdDrug
Subjects will receive 1800 mg US-DARZALEX FASPRO® via SC administration for up to 16 weeks: weekly during Week 1-8 (Cycle 1-2; 1 cycle = 4 weeks) and every two weeks during Week 9-16 (Cycle 3-4).
Primary outcomes
What the sponsor says the trial is designed to measure.
- pharmacokinetic (PK) similarityTime frame: 7 days
- pharmacokinetic (PK) similarityTime frame: 7 days
- pharmacokinetic (PK) similarityTime frame: 16 weeks
- pharmacokinetic (PK) similarityTime frame: 16 weeks
Locations
84 sites in 5 countries. Site status is shown where the registry gives one.
Highlands Oncology Group, PA
Springdale, Arkansas · Recruiting
Cancer Specialists of North Florida
Jacksonville, Florida · Recruiting
D&H National Research Center
Margate, Florida · Recruiting
Ocala Oncology Center
Ocala, Florida · Recruiting
Florida Clinical Trials Group
Plantation, Florida · Recruiting
Florida Clinical Trials Group
Tamarac, Florida · Recruiting
Genesis Medical Research
Dyer, Indiana · Recruiting
Pontchartrain Cancer Center
Covington, Louisiana · Recruiting
Oncology Consultants (P1 Trials -Exigent Network)
Houston, Texas · Recruiting
Lumi Research
Houston, Texas · Recruiting
Optum Care Washington
Everett, Washington · Recruiting
American Oncology Network Vista Oncology Division / Physician partner associate
Olympia, Washington · Recruiting
Perth Blood Institute
Perth, Australia · Recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Chao-Yang Hospital Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Guangzhou First People's Hospital
Guangzhou, Guangdong, China · Recruiting
Guangdong General Hospital
Guangzhou, Guangdong, China · Recruiting
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Meizhou People's Hospital
Meizhou, Guangdong, China · Recruiting
Shenzhen People's Hospital
Shenzhen, Guangdong, China · Recruiting
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Liuzhou Worker's Hospital
Liuzhou, Guangxi, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
Affiliated Hospital of Hebei University
Baoding, Hebei, China · Recruiting
Cangzhou People's Hospital
Cangzhou, Hebei, China · Recruiting
Hebei medical university third hospital
Shijiazhuang, Hebei, China · Recruiting
The Second Hospital of Hebei Medical Universit
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Henan University of Science & Techinology
Luoyang, Henan, China · Recruiting
Xinxiang Central Hospital
Xinxiang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.